Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Fineline Cube Dec 16, 2025
Company Deals

uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials

Fineline Cube Dec 16, 2025
Company Deals

Dren Bio, Sanofi Forge $1.8B B‑Cell Therapy Deal with US Co‑Promote Option

Fineline Cube Dec 16, 2025
Company Deals

Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis

Fineline Cube Dec 16, 2025
Company Deals

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Fineline Cube Dec 15, 2025
Policy / Regulatory

FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data

Fineline Cube Dec 16, 2025
Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Fineline Cube Dec 16, 2025
Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Fineline Cube Dec 16, 2025
Company Drug

Henlius’ PD-1 Inhibitor HanSiZhuang Approved for First-Line SCLC Indication

Fineline Cube Jan 17, 2023

Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced receiving another indication approval from China’s...

Company Medical Device

Agilis Robotics Completes Successful Animal Testing for Surgical Robot

Fineline Cube Jan 17, 2023

Hong Kong-based Agilis Robotics Ltd has successfully completed a second round of live animal testing...

Company Deals

CARsgen and Huadong Medicine Partner to Commercialize BCMA CAR-T Product CT053 in China

Fineline Cube Jan 17, 2023

China-based CARsgen Therapeutics Holdings Limited (HKG: 2171), a leading developer of innovative CAR T-cell therapies,...

Company Deals

Tongshu Gene Partners with LC Gene to Distribute Gene Mutation Detection Kit in China

Fineline Cube Jan 17, 2023

China-based gene testing service providers Tongshu Gene and LC Gene Diagnostics (Hangzhou) Co., Ltd. have...

Company Drug

3D Medicines’ 3D185 Receives Orphan Drug Designation for Gastric Cancer

Fineline Cube Jan 16, 2023

China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving orphan drug designation (ODD) status...

Company Drug

Ascletis Pharma Initiates Dosing in Phase I Trial for COVID-19 Treatment ASC11

Fineline Cube Jan 16, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced the dosing of four healthy subjects in...

Company Deals

Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines

Fineline Cube Jan 16, 2023

Base Therapeutics, a Guangdong-based firm specializing in base editing and prime editing technologies, has reportedly...

Company Deals

ConceMed Raises Pre-Series A Funding to Expand Digestive Endoscope Pipeline

Fineline Cube Jan 16, 2023

ConceMed, a Guangdong-based maker of digestive soft electronic endoscopes, has reportedly raised “tens of millions”...

Company Drug

Luye Pharma’s Rykindo Receives FDA Approval for Schizophrenia and Bipolar I Disorder

Fineline Cube Jan 16, 2023

China-based Luye Pharma Group (HKG: 2186) has announced receiving market approval from the US Food...

Company

WuXi Biologics CEO Outlines Growth Amid Global Challenges at J.P. Morgan Conference

Fineline Cube Jan 16, 2023

China-based WuXi Biologics (HKG: 2269) delivered a speech at the J.P. Morgan Healthcare Conference, where...

Company Drug

Hengrui’s Generic Cyclophosphamide Capsules Approved by China’s NMPA

Fineline Cube Jan 16, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving marketing approval from the National Medical...

Company Deals

ReLive Biotechnologies Acquires Co.Don AG, Secures USD 36 Million for Expansion

Fineline Cube Jan 16, 2023

Tissue engineering and regenerative medicine start-up ReLive Biotechnologies Ltd has announced the full acquisition of...

Company Drug

Akeso’s Penpulimab Secures New Approval for Lung Cancer Indication

Fineline Cube Jan 16, 2023

China-based Akeso Biopharma (HKG: 9926) has announced receiving another indication approval from the National Medical...

Company Drug

Clover Biopharmaceuticals Plans COVID-19 Vaccine SCB-2019 Launch in China for 2023

Fineline Cube Jan 16, 2023

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has provided updates on its plans for the commercialization...

Company Drug

Amoytop’s AK0706 Receives Clinical Trial Approval for Hepatitis B Treatment

Fineline Cube Jan 16, 2023

Xiamen-based Amoytop Biotech Co. Ltd has announced receiving clinical trial approval from China’s National Medical...

Company Deals

JHM Biopharma Raises RMB100 Million to Expand Protein Drug Pipeline

Fineline Cube Jan 16, 2023

Hangzhou-based protein drug developer JHM Biopharma has reportedly secured close to RMB100 million (USD14.9 million)...

Company Drug

Sino Biopharma’s PD-L1 Combo with Anlotinib Accepted for Review by China’s CDE

Fineline Cube Jan 16, 2023

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its New Drug Application (NDA) filing...

Company Deals

Meheco’s Genertec Partners with AstraZeneca for COVID-19 Antibody Evusheld in China

Fineline Cube Jan 16, 2023

China Meheco Group Co., Ltd (SHA: 600056) announced that its subsidiary Genertec Meheco has entered...

Company Drug

Guangzhou’s Overseas Pharma Wins China Clinical Trial Approval for OPL-038

Fineline Cube Jan 16, 2023

Guangzhou-based Overseas Pharmaceuticals, Ltd has secured clinical trial approval in China for its sustained and...

Company Deals

Eyougene Raises Hundreds of Millions in Series B Funding for Expansion

Fineline Cube Jan 13, 2023

Eyougene Co., Ltd, a digital Contract Development and Manufacturing Organization (CDMO) based in Shanghai, has...

Posts pagination

1 … 505 506 507 … 598

Recent updates

  • Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared
  • Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal
  • Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway
  • ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy
  • FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Company Medical Device

Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway

Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.